CATALYST PHARMACEUTICALS, INC.
CATALYST PHARMACEUTICALS, INC. (CPRX): 6 pipeline candidates · 3 upcoming catalysts · ~47 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
46.8 months
D/E 0.13 · 4% dilution
Lead: Approved
6 candidates
3 upcoming, next in ~13d
N/A
A transparent, data-derived signal for CATALYST PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.8B
Cash
$755.9M
Quarterly Burn
$52.0M
Runway
46.8 mo
Revenue
$149.4M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (6 candidates)
Upcoming Catalysts (3)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
379
Total value held
$2.70B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 18,774,530 | $464.9M |
| vanguard capital management llc | 10,245,332 | $253.7M |
| state street corp | 6,863,060 | $169.9M |
| american century companies inc | 4,138,416 | $102.5M |
| janus henderson group plc | 3,997,750 | $99.0M |
| deerfield management company, l.p. | 3,943,600 | $97.6M |
| dimensional fund advisors lp | 3,429,615 | $84.9M |
| bank of america corp /de/ | 3,036,546 | $75.2M |
| geode capital management, llc | 2,972,402 | $73.6M |
| morgan stanley | 2,687,299 | $66.5M |
Showing top 10 of 379 institutional holders of CATALYST PHARMACEUTICALS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in CATALYST PHARMACEUTICALS, INC.'s pipeline?
CATALYST PHARMACEUTICALS, INC. (CPRX) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CATALYST PHARMACEUTICALS, INC.'s lead drug candidate?
CATALYST PHARMACEUTICALS, INC.'s most advanced tracked candidate is agamree (Approved) for Duchenne muscular dystrophy (DMD).
What is CATALYST PHARMACEUTICALS, INC.'s next catalyst?
CATALYST PHARMACEUTICALS, INC.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: FYCOMPA" — expected July 1, 2026.
What is CATALYST PHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CATALYST PHARMACEUTICALS, INC. has approximately 46.8 months of cash runway.
What is CATALYST PHARMACEUTICALS, INC.'s market capitalization?
CATALYST PHARMACEUTICALS, INC.'s market capitalization is approximately $3.8B.
Get the full picture on CATALYST PHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.